Europe Clinical Laboratory Services Market Size | Companies
The Europe clinical laboratory services market size was exhibited at USD 68.15 billion in 2023 and is projected to hit around USD 86.39 billion by 2033, growing at a CAGR of 2.4% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 69.79 Billion |
| Market Size by 2033 | USD 86.39 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 2.4% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Test type, Service Provider, Application, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | Germany; UK; France; Italy; RoE |
| Key Companies Profiled | Eurofins Scientific; SYNLAB International GmbH; UNILABS; Quest Diagnostics Incorporated; Sonic Healthcare Limited; NeoGenomics Laboratories; ARUP Laboratories; Mayo Foundation for Medical Education and Research |
Market growth can be attributed to the significant increase in collaborations between European universities and clinical laboratory service providers. This trend has led to the development of cutting-edge research and innovative technologies, driving advancements in diagnostics and treatment options.
In 2023, the Europe region accounted for approximately 29.3% revenue share of the global clinical laboratory services market. The industry is driven by various initiatives undertaken by government and private organizations. These efforts aim to fund research and development in clinical laboratory tests and services, as well as promote awareness about early diagnosis.
Key government organizations, such as the European Organization for Research and Treatment of Cancer (EORTC), the European Medicines Agency (EMA), and the National Health Service (NHS), are working together to develop a comprehensive program focused on improving diagnosis in the region. For instance, the UK government has made £2.3 billion available for reform diagnostics in England, establishing over 155 Community Diagnostic Centers that have delivered over 7 million tests, checks, and scans across the country as of March 2023.
The COVID-19 pandemic has accelerated the adoption of advanced diagnostic technologies in Europe, including chemiluminescence immunoassays, real-time PCR, mass spectrometry, flow cytometry, and high-throughput assays. Countries such as Germany, Italy, the UK, and France are leading the way in implementing these cutting-edge technologies, enhancing the accuracy, efficiency, and accessibility of clinical testing, and driving market growth across the region.
Clinical chemistry tests emerged as the dominant market segment in 2023, accounting for 51.2% of the total revenue. Clinical chemistry tests are essential for primary diagnosis and laboratory testing, using techniques like spectrophotometry, immunoassay, and electrophoresis. The market is driven by innovations in chronic kidney disease, heart failure, and osteoporosis testing.
Human & tumor genetics testing is expected to experience the fastest CAGR of 6.5% over the forecast period. In countries with advanced healthcare infrastructure and a focus on precision medicine, the demand for personalized care with accurate and early diagnosis in oncology is driving growth. The adoption of next-generation sequencing and other cutting-edge diagnostic technologies is also accelerating market expansion in Europe.
In 2023, hospital-based laboratories led the service providers segment, accounting for over 50.15% of the total revenue. This dominance is expected to continue as more hospitals integrate laboratories into their facilities, driven by the increasing number of outreach programs and the high demand for timely testing and diagnosis of complex and major diseases.
Clinic-based laboratories are expected to experience a lucrative CAGR of 3.2% over the forecast period. The segment growth is driven by the increasing demand for diagnostic testing, technological advancements, and the adoption of Point-Of-Care testing. The integration of Laboratory Information Systems with electronic health records also improves workflow efficiency and data sharing, while accreditation ensures high-quality and reliable results.
Bioanalytical & lab chemistry services held the largest market share in 2023, accounting for 53.9% of the total revenue. European laboratories are harnessing the power of advanced technologies such as mass spectrometry and flow cytometry to transform clinical chemistry analysis, delivering precise, efficient, and accessible testing services. Moreover, the surge in research activities focused on genetic and proteomic studies of hereditary and gene-mutation disorders is expected to drive revenue growth for this segment over the forecast period.
The toxicology testing services segment is anticipated to exhibit the most rapid growth, with a projected CAGR of 7.6% over the forecast period. Stringent regulatory standards and a focus on product safety across industries, such as pharmaceuticals and chemicals, are key drivers. Moreover, the increasing demand for specialized toxicology testing services tailored to specific industries and applications is also contributing to the market growth.
Germany Clinical Laboratory Services Market Trends
The Germany clinical laboratory services market held the largest market share in the Europe region, accounting for 20.8% of the total revenue in 2023. This large share is attributed to the presence of many laboratories and access to innovative technologies. The country’s favorable reimbursement environment, characterized by higher prices set by manufacturers, also contributed to its market share.
The aging population, paired with the rising incidence of chronic diseases, is fueling the demand for clinical laboratory services in the UK, particularly for early and accurate disease diagnosis. A significant number of tests are conducted in the UK every year. According to the NHS, in England, over 1.12 billion pathology tests are performed every year, with private labs facing competition from low-cost NHS tests. Thus, the country has been at the forefront of investing in diagnostic testing, particularly in response to the COVID-19 pandemic.
France Clinical Laboratory Services Market Trends
The France clinical laboratory services market is expected to experience rapid growth over the forecast period, with a CAGR of 3.4% from 2024 to 2033, driven by the increasing prevalence of infectious diseases, technological advancements, and consumer awareness. The elderly population (21.7% of France’s population in 2022, as reported by the World Bank) requires more diagnostic services, making clinical laboratory services essential for accurate diagnosis and treatment.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe clinical laboratory services market
Test Type
Service Provider
Application
Country
Chapter 1 Clinical Laboratory Services Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 Global Market: Cagr Calculation
1.9 List Of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List Of Abbreviations
Chapter 2 Clinical Laboratory Services Market: Executive Summary
2.1 Clinical Laboratory Services Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Clinical Laboratory Services Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Technological Advancements In The Filed Of Clinical Testing
3.3.1.2 Growing Prevalence Of Target Diseases Coupled With Rising Demand For Early Disease Diagnostic Tests
3.3.1.3 Introduction Of Novel Solutions
3.3.1.4 Introduction Of Home Health Tests
3.3.1.5 Outbreak Of Coivd-19 Technologies
3.3.2 Market Restraint Analysis
3.3.2.1 Presence Of Stringent Regulatory Framework
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4. Clinical Laboratory Services Market: Test Type Estimates & Trend Analysis
4.1. Test Type Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Global Clinical Laboratory Services Market by Test Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Genetic Testing
4.4.1.1. Market estimates and forecasts, 2021 to 2033
4.4.2. Clinical Chemistry
4.4.2.1. Market estimates and forecasts, 2021 to 2033
4.4.2.2. Routine Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.3. Therapeutic Drug Monitoring Testing Market estimates and forecasts, 2021 to 2033
4.4.2.4. Endocrinology Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.5. Specialized Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.6. Other Clinical Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.3. Medical Microbiology Testing
4.4.3.1. Market estimates and forecasts, 2021 to 2033
4.4.3.2. Infectious Disease Testing Market estimates and forecasts, 2021 to 2033
4.4.3.3. Transplant Diagnostic Testing Market estimates and forecasts, 2021 to 2033
4.4.3.4. Other Microbiology Testing Market estimates and forecasts, 2021 to 2033
4.4.4. Hematology Testing
4.4.5. Immunology Testing
4.4.6. Cytology Testing
4.4.7. Drug of Abuse Testing
4.4.8. Other Esoteric Tests
4.4.8.1. Market estimates and forecasts, 2021 to 2033
Chapter 5. Clinical Laboratory Services Market: Service Provider Estimates & Trend Analysis
5.1. Service Provider Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Clinical Laboratory Services Market by Service Provider Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Hospital-Based Laboratories
5.4.1.1. Market estimates and forecasts, 2021 to 2033
5.4.2. Stand-Alone Laboratories
5.4.2.1. Market estimates and forecasts, 2021 to 2033
5.4.3. Clinic-Based Laboratories
5.4.3.1. Market estimates and forecasts, 2021 to 2033
Chapter 6. Clinical Laboratory Services Market: Application Estimates & Trend Analysis
6.1. Application Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Clinical Laboratory Services Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Bioanalytical & Lab Chemistry Services
6.4.1.1. Market estimates and forecasts, 2021 to 2033
6.4.2. Toxicology Testing Services
6.4.2.1. Market estimates and forecasts, 2021 to 2033
6.4.3. Cell & Gene Therapy Related Services
6.4.3.1. Market estimates and forecasts, 2021 to 2033
6.4.4. Preclinical & Clinical Trial Related Services
6.4.4.1. Market estimates and forecasts, 2021 to 2033
6.4.5. Drug Discovery & Development Related Services
6.4.5.1. Market estimates and forecasts, 2021 to 2033
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2021 to 2033
Chapter 7. Clinical Laboratory Services Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts, 2021 to 2033
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts, 2021 to 2033
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts, 2021 to 2033
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts, 2021 to 2033
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts, 2021 to 2033
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts, 2021 to 2033
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts, 2021 to 2033
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts, 2021 to 2033
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts, 2021 to 2033
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts, 2021 to 2033
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts, 2021 to 2033
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts, 2021 to 2033
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts, 2021 to 2033
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts, 2021 to 2033
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts, 2021 to 2033
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts, 2021 to 2033
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts, 2021 to 2033
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts, 2021 to 2033
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts, 2021 to 2033
7.8.4. Colombia
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework/ reimbursement structure
7.8.4.3. Competitive scenario
7.8.4.4. Colombia market estimates and forecasts, 2021 to 2033
7.8.5. Peru
7.8.5.1. Key country dynamics
7.8.5.2. Regulatory framework/ reimbursement structure
7.8.5.3. Competitive scenario
7.8.5.4. Peru market estimates and forecasts, 2021 to 2033
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts, 2021 to 2033
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts, 2021 to 2033
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. QIAGEN NV
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. QUEST DIAGNOSTICS INCORPORATED
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. OPKO HEALTH, INC
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. CHARLES RIVER LABORATORIES
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. ARUP LABORATORIES (ASSOCIATED REGIONAL AND UNIVERSITY PATHOLOGISTS, INC.)
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. SONIC HEALTHCARE
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. NEOGENOMICS LABORATORIES, INC.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. FRESENIUS MEDICAL CARE AG & CO. KGAA
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. SIEMENS HEALTHCARE LIMITED
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. SYNLAB International GmbH
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. Mayo Clinic Laboratories
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Unilabs
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Product benchmarking
8.3.16.4. Strategic initiatives
8.3.17. Eurofins Scientific SE
8.3.17.1. Company overview
8.3.17.2. Financial performance
8.3.17.3. Product benchmarking
8.3.17.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers